-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche's Vabysmo Shows Sustained Two-Year Results In SALWEEN Study, With 61% Of PCV Patients Achieving Extended 20-Week Dosing

Benzinga·08/28/2026 07:09:38
Listen to the news
  • The SALWEEN study showed significant improvements in vision and retinal health
  • More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no signs of polypoidal lesions
  • By the end of year two, more than 60% of patients were on an extended 20-week treatment interval, reducing treatment burden
  • Vabysmo was well tolerated with a consistent long-term safety profile